Nephrogenex Inc. (NRX) 6.67 $NRX
NephroGenex to Present at the 17th Annual BIO CEO & Investor Conference
Business Wire - Mon Feb 02, 7:00AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer Pierre Legault will present a corporate overview of the Company and meet with investors at the 17th Annual BIO CEO & Investor Conference in New York City.
NRX: 6.67 (-0.14)
Nephrogenex to Present at the Noble Financial Capital Markets Equity Conference
Business Wire - Wed Jan 14, 7:00AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer, Pierre Legault will present a corporate overview of the Company at the Noble Financial Capital Markets Eleventh Annual Equity Conference in Sandpiper, Florida.
NRX: 6.67 (-0.14)
Today's Review on Biotech Equities - Kite Pharma, Organovo Holdings, BioMarin Pharma, NephroGenex, and Neuralstem
PR Newswire - Fri Jan 09, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: Kite Pharma Inc. (NASDAQ: KITE), Organovo Holdings Inc. (NYSE MKT: ONVO), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), NephroGenex Inc. (NASDAQ: NRX), and Neuralstem Inc. (NYSE MKT: CUR). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets surged on Thursday, January 08, 2015, as the Dow Jones Industrial Average finished at 17,907.87, up 1.84% and the NASDAQ Composite closed at 4,736.19, up 1.84%. The S&P 500 finished the session 1.79% higher at 2,062.14. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 819.86, up 1.72%, with the index gaining 11.71% in the previous three months. Register for your complimentary reports on these five stocks at:
BMRN: 100.76 (+1.98), KITE: 62.59 (+0.82), ONVO: 6.34 (+0.07), NRX: 6.67 (-0.14), CUR: 3.41 (+0.13)
InsiderInsights.com Daily Round Up 1/6/15: XOMA, CODI, MNST, BBY
InsiderInsights - at Seeking Alpha - Thu Jan 08, 9:37AM CST
MNST: 117.74 (-1.77), CODI: 16.61 (+0.03), MILL: 2.07 (+0.09), NRX: 6.67 (-0.14), BBY: 39.11 (-0.08), FUND: 7.47 (+0.05), LVS: 60.43 (+1.71), SPB: 94.05 (+0.80), QVCA: 29.47 (+0.42), LMCA: 37.97 (+0.06), BGH: 21.24 (+0.06), SIX: 45.11 (-0.05), AGIO: 118.55 (+0.11), XOMA: 3.41 (-0.01), JGV: 12.93 (+0.09)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:15AM CST
NRX: 6.67 (-0.14), BIND: 6.06 (+0.21), NBG: 1.61 (+0.18), MBT: 10.36 (+0.62), STML: 14.07 (-0.10), BIOD: 1.38 (-0.14), SIG: 120.19 (+0.36), PBR: 6.98 (+0.44), NBIX: 37.22 (+0.27), PIR: 12.52 (+0.17), VLCCF: 4.15 (-0.06), CONN: 24.69 (-0.07), CYTR: 2.96 (+0.23), PLX: 1.84 (-0.04), MEET: 1.78 (+0.02), INFI: 15.13 (+0.55), CYRN: 2.83 (+0.23), APOL: 25.97 (+0.33), CJJD: 2.59 (-0.01), CRK: 6.09 (+0.46), FOLD: 8.36 (-0.11), GST: 2.89 (unch)
NephroGenex up on positive feedback from EMA on Pyridorin trial
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 7:02AM CST
NRX: 6.67 (-0.14)
NephroGenex Announces that the European Medicines Agency Supports the Company's Study Design for Ongoing Trial in Diabetic Nephropathy
Business Wire - Wed Jan 07, 4:00PM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that the Company has received positive Scientific Advice from the European Medicines Agency (EMA) regarding their Phase 3 program with Pyridorin(R) in diabetic nephropathy that has been accepted by the U.S. Food and Drug Administration under a Special Protocol Assessment. The EMA indicated that the current Phase 3 program could be adequate to support a Marketing Authorization Application for full market approval in Europe.
NRX: 6.67 (-0.14)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 11:50AM CST
JBSS: 37.24 (-0.26), MELA: 1.55 (+0.09), SYRX: 1.50 (-0.06), NRX: 6.67 (-0.14), NKA: 1.68 (+0.13), PRTK: 26.95 (+0.65), JOB: 0.79 (+0.01), HNR: 0.69 (+0.03), BCLI: 3.86 (-0.02), QTWW: 2.96 (-0.04), CHNR: 1.91 (+0.01), PWRD: 18.95 (+0.02), CJJD: 2.59 (-0.01), WTW: 18.16 (+0.33), LOCK: 14.10 (-0.19), MDXG: 8.65 (+0.23), GNI: 10.94 (+0.15), ATEA: 1.76 (+0.01), EXEL: 2.48 (+0.20)
NephroGenex faces profit taking today
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 8:15AM CST
NRX: 6.67 (-0.14)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 8:14AM CST
KOOL: 0.88 (-0.14), BLDP: 2.66 (-0.26), PBR: 6.98 (+0.44), LNCO: 12.30 (+0.28), KITE: 62.59 (+0.82), NRX: 6.67 (-0.14), LINE: 12.94 (+0.40), PWRD: 18.95 (+0.02), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
NephroGenex Hits 52-Week High on Pyridorin Safety Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 7:40AM CST
NephroGenex, Inc. (NRX) announced that its diabetic nephropathy candidate, Pyridorin, was found to be safe in a cardiac safety study (thorough QT/QTc (TQT) analysis).
LCI: 57.78 (-0.91), NRX: 6.67 (-0.14), BMY: 60.04 (+0.56), SNY: 49.42 (+0.82)
NephroGenex (NRX) Stock Skyrockets to One-Year High Today After Lead Drug Safety Announcement
at The Street - Wed Dec 31, 10:27AM CST
Shares of drug developer NephroGenex (NRX) exploded to a 52-week high Wednesday after the company announced it found its lead drug to be safe in a cardiac safety study.
NRX: 6.67 (-0.14)
Daily Pharma Dose: New Research on Hospira, Aquinox, Sucampo, NephroGenex and OncoGenex
PR Newswire - Wed Dec 31, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Hospira (NYSE: HSP), Aquinox (NASDAQ: AQXP), Sucampo (NASDAQ: SCMP), NephroGenex (NASDAQ: NRX), and OncoGenex (NASDAQ: OGXI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AQXP: 10.29 (-0.54), OGXI: 2.06 (-0.05), NRX: 6.67 (-0.14), SCMP: 15.32 (+0.04), HSP: 87.35 (unch)
NephroGenex up big on Pyridorin safety study
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 7:52AM CST
NRX: 6.67 (-0.14)
NephroGenex Announces Positive Results for QT Study of Pyridorin
Business Wire - Tue Dec 30, 3:05PM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the Company has successfully completed a thorough QT/QTc (TQT) cardiac safety study on Pyridorin. This study assesses a drug's risk of QT prolongation and its proarrhythmic potential, and is a standard component of all clinical development programs for new molecular entities.
NRX: 6.67 (-0.14)
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/6lddwg/acute_renal) has announced the addition of the "Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Quark Pharmaceuticals, Inc. - FibroGen, Inc. - Novartis AG - Hadasit Medical Research Services & Development Ltd - NephroGenex, Inc. - Torrent Pharmaceuticals Limited - Digna Biotech, S.L. - Am-Pharma B.V. - AlloCure Inc. - Angion Biomedica Corp. - Thrasos, Inc. - Bolder Biotechnology, Inc. - Kringle Pharma, Inc. - Nephrx Corporation - STATegics, Inc. - ACROVIS biostructures GmbH - Nyken BV - AbbVie Inc. - Adrenomed AG For more information visit http://www.researchandmarkets.com/research/6l...cute_renal
NRX: 6.67 (-0.14), FGEN: 30.25 (+0.50), ABBV: 58.05 (+1.00), NVS: 102.20 (-0.17)
NephroGenex Announces Closing of $12 Million Term Loan Facility
Business Wire - Thu Nov 20, 3:05PM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, announced today that it has closed on a $12 million term loan facility with East West Bank. Funds from the term loan will be utilized for working capital purposes, including the advancement of the Company's clinical development programs.
NRX: 6.67 (-0.14)
NephroGenex to Present at the 17th Annual BIO CEO & Investor Conference
Business Wire - Mon Feb 02, 7:00AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer Pierre Legault will present a corporate overview of the Company and meet with investors at the 17th Annual BIO CEO & Investor Conference in New York City.
NRX: 6.67 (-0.14)
Nephrogenex to Present at the Noble Financial Capital Markets Equity Conference
Business Wire - Wed Jan 14, 7:00AM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer, Pierre Legault will present a corporate overview of the Company at the Noble Financial Capital Markets Eleventh Annual Equity Conference in Sandpiper, Florida.
NRX: 6.67 (-0.14)
Today's Review on Biotech Equities - Kite Pharma, Organovo Holdings, BioMarin Pharma, NephroGenex, and Neuralstem
PR Newswire - Fri Jan 09, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: Kite Pharma Inc. (NASDAQ: KITE), Organovo Holdings Inc. (NYSE MKT: ONVO), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), NephroGenex Inc. (NASDAQ: NRX), and Neuralstem Inc. (NYSE MKT: CUR). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets surged on Thursday, January 08, 2015, as the Dow Jones Industrial Average finished at 17,907.87, up 1.84% and the NASDAQ Composite closed at 4,736.19, up 1.84%. The S&P 500 finished the session 1.79% higher at 2,062.14. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 819.86, up 1.72%, with the index gaining 11.71% in the previous three months. Register for your complimentary reports on these five stocks at:
BMRN: 100.76 (+1.98), KITE: 62.59 (+0.82), ONVO: 6.34 (+0.07), NRX: 6.67 (-0.14), CUR: 3.41 (+0.13)
InsiderInsights.com Daily Round Up 1/6/15: XOMA, CODI, MNST, BBY
InsiderInsights - at Seeking Alpha - Thu Jan 08, 9:37AM CST
MNST: 117.74 (-1.77), CODI: 16.61 (+0.03), MILL: 2.07 (+0.09), NRX: 6.67 (-0.14), BBY: 39.11 (-0.08), FUND: 7.47 (+0.05), LVS: 60.43 (+1.71), SPB: 94.05 (+0.80), QVCA: 29.47 (+0.42), LMCA: 37.97 (+0.06), BGH: 21.24 (+0.06), SIX: 45.11 (-0.05), AGIO: 118.55 (+0.11), XOMA: 3.41 (-0.01), JGV: 12.93 (+0.09)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 8:15AM CST
NRX: 6.67 (-0.14), BIND: 6.06 (+0.21), NBG: 1.61 (+0.18), MBT: 10.36 (+0.62), STML: 14.07 (-0.10), BIOD: 1.38 (-0.14), SIG: 120.19 (+0.36), PBR: 6.98 (+0.44), NBIX: 37.22 (+0.27), PIR: 12.52 (+0.17), VLCCF: 4.15 (-0.06), CONN: 24.69 (-0.07), CYTR: 2.96 (+0.23), PLX: 1.84 (-0.04), MEET: 1.78 (+0.02), INFI: 15.13 (+0.55), CYRN: 2.83 (+0.23), APOL: 25.97 (+0.33), CJJD: 2.59 (-0.01), CRK: 6.09 (+0.46), FOLD: 8.36 (-0.11), GST: 2.89 (unch)
NephroGenex up on positive feedback from EMA on Pyridorin trial
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 7:02AM CST
NRX: 6.67 (-0.14)
NephroGenex Announces that the European Medicines Agency Supports the Company's Study Design for Ongoing Trial in Diabetic Nephropathy
Business Wire - Wed Jan 07, 4:00PM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that the Company has received positive Scientific Advice from the European Medicines Agency (EMA) regarding their Phase 3 program with Pyridorin(R) in diabetic nephropathy that has been accepted by the U.S. Food and Drug Administration under a Special Protocol Assessment. The EMA indicated that the current Phase 3 program could be adequate to support a Marketing Authorization Application for full market approval in Europe.
NRX: 6.67 (-0.14)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 11:50AM CST
JBSS: 37.24 (-0.26), MELA: 1.55 (+0.09), SYRX: 1.50 (-0.06), NRX: 6.67 (-0.14), NKA: 1.68 (+0.13), PRTK: 26.95 (+0.65), JOB: 0.79 (+0.01), HNR: 0.69 (+0.03), BCLI: 3.86 (-0.02), QTWW: 2.96 (-0.04), CHNR: 1.91 (+0.01), PWRD: 18.95 (+0.02), CJJD: 2.59 (-0.01), WTW: 18.16 (+0.33), LOCK: 14.10 (-0.19), MDXG: 8.65 (+0.23), GNI: 10.94 (+0.15), ATEA: 1.76 (+0.01), EXEL: 2.48 (+0.20)
NephroGenex faces profit taking today
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 8:15AM CST
NRX: 6.67 (-0.14)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Jan 02, 8:14AM CST
KOOL: 0.88 (-0.14), BLDP: 2.66 (-0.26), PBR: 6.98 (+0.44), LNCO: 12.30 (+0.28), KITE: 62.59 (+0.82), NRX: 6.67 (-0.14), LINE: 12.94 (+0.40), PWRD: 18.95 (+0.02), BCLI: 3.86 (-0.02), CUR: 3.41 (+0.13)
NephroGenex Hits 52-Week High on Pyridorin Safety Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 7:40AM CST
NephroGenex, Inc. (NRX) announced that its diabetic nephropathy candidate, Pyridorin, was found to be safe in a cardiac safety study (thorough QT/QTc (TQT) analysis).
LCI: 57.78 (-0.91), NRX: 6.67 (-0.14), BMY: 60.04 (+0.56), SNY: 49.42 (+0.82)
NephroGenex (NRX) Stock Skyrockets to One-Year High Today After Lead Drug Safety Announcement
at The Street - Wed Dec 31, 10:27AM CST
Shares of drug developer NephroGenex (NRX) exploded to a 52-week high Wednesday after the company announced it found its lead drug to be safe in a cardiac safety study.
NRX: 6.67 (-0.14)
Daily Pharma Dose: New Research on Hospira, Aquinox, Sucampo, NephroGenex and OncoGenex
PR Newswire - Wed Dec 31, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Hospira (NYSE: HSP), Aquinox (NASDAQ: AQXP), Sucampo (NASDAQ: SCMP), NephroGenex (NASDAQ: NRX), and OncoGenex (NASDAQ: OGXI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AQXP: 10.29 (-0.54), OGXI: 2.06 (-0.05), NRX: 6.67 (-0.14), SCMP: 15.32 (+0.04), HSP: 87.35 (unch)
NephroGenex up big on Pyridorin safety study
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 7:52AM CST
NRX: 6.67 (-0.14)
NephroGenex Announces Positive Results for QT Study of Pyridorin
Business Wire - Tue Dec 30, 3:05PM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced the Company has successfully completed a thorough QT/QTc (TQT) cardiac safety study on Pyridorin. This study assesses a drug's risk of QT prolongation and its proarrhythmic potential, and is a standard component of all clinical development programs for new molecular entities.
NRX: 6.67 (-0.14)
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/6lddwg/acute_renal) has announced the addition of the "Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline depth and focus of Indication therapeutics Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Quark Pharmaceuticals, Inc. - FibroGen, Inc. - Novartis AG - Hadasit Medical Research Services & Development Ltd - NephroGenex, Inc. - Torrent Pharmaceuticals Limited - Digna Biotech, S.L. - Am-Pharma B.V. - AlloCure Inc. - Angion Biomedica Corp. - Thrasos, Inc. - Bolder Biotechnology, Inc. - Kringle Pharma, Inc. - Nephrx Corporation - STATegics, Inc. - ACROVIS biostructures GmbH - Nyken BV - AbbVie Inc. - Adrenomed AG For more information visit http://www.researchandmarkets.com/research/6l...cute_renal
NRX: 6.67 (-0.14), FGEN: 30.25 (+0.50), ABBV: 58.05 (+1.00), NVS: 102.20 (-0.17)
NephroGenex Announces Closing of $12 Million Term Loan Facility
Business Wire - Thu Nov 20, 3:05PM CST
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, announced today that it has closed on a $12 million term loan facility with East West Bank. Funds from the term loan will be utilized for working capital purposes, including the advancement of the Company's clinical development programs.
NRX: 6.67 (-0.14)
